The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex Pharmaceuticals is cranking up the charm on Wall Street with a whopping $4 billion share buyback plan, signaling ...

Diatoms turns a weird Victorian art craze into a solid competitive board game that also has a solo campaign. Read Keith Law's ...

Google I/O has kicked off in Mountain View, California, and the initial keynote provided a laundry list of big AI ...

At its annual developer conference, Google I/O 2025, the company introduced generative AI tools focused on image, video, and ...

Shares of gene therapy specialist, CRISPR Therapeutics (NASDAQ: CRSP) have been beaten down a long way despite some ...

it comes in a once-daily rather than twice-daily pill form, and it's decreased sweat chloride levels even more than Trikafta -- lower levels suggest better protein function. Last year, Vertex's ...

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

“Vertex continued to perform well in the first ... the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities ...